Skip to content
AnalystLens

MEDP · Medpace Holdings

90 filings

8-K

MEDP 8-K Current Reports

Medpace Holdings - 90 current reports

Filing record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Change in control8-K · Jun ’17Jun ’17
  2. Leadership change8-K · May ’19May ’19
  3. Leadership change8-K · Jul ’21Jul ’21
  4. Material agreement8-K · Jul ’25Jul ’25
Showing 1-50 of 90 filings
8-K
Earnings & ResultsOther EventsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Oct 21, 2026)

Medpace Holdings, Inc. reported third quarter 2026 results on October 21, 2026, as furnished under Item 2.02 with the press release attached as Exhibit 99.1. Revenue for the quarter was $716.0 million, up 8.5% from $659.9 million a year earlier, and the backlog conversion rate was 23.8%. Net new business awards were $873.4 million, up 10.6% from $789.6 million. GAAP net income was $137.5 million, or $4.84 per diluted share, versus $111.1 million, or $3.86 per diluted share, in the prior-year quarter. EBITDA was $172.1 million, up 16.0%, with an EBITDA margin of 24.0%. Backlog as of September 30, 2026 was $3,167.2 million, up 5.6%. For the nine months ended September 30, 2026, revenue was $2,129.9 million, up 16.9% on a reported basis, and GAAP net income was $382.7 million, or $13.37 per diluted share. The company forecasts 2026 revenue of $2.835 billion to $2.855 billion, GAAP net income of $514.0 million to $524.0 million, and diluted EPS of $17.97 to $18.32. Guidance excludes any share repurchases made after September 30, 2026. Under Item 8.01, the Board terminated the existing repurchase authorization, which had $527.0 million remaining and was set to expire December 31, 2026, effective October 20, 2026, and approved a new authorization of up to $1.0 billion of common stock through December 31, 2028. Repurchases are to be funded from cash on hand, and the authorization may be modified or terminated at any time. The company reported cash and cash equivalents of $705.3 million at September 30, 2026, and no share repurchases in the third quarter.

Oct 21, 2026
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Jul 22, 2026)

Medpace Holdings, Inc. reported second quarter 2026 results in a press release furnished as Exhibit 99.1 to this Form 8-K. Revenue was $707.3 million, up 17.2% from $603.3 million a year earlier, and GAAP net income was $121.4 million, or $4.25 per diluted share, versus $90.3 million, or $3.10 per diluted share, in the prior-year quarter. EBITDA was $153.4 million, up 17.6%, with an EBITDA margin of 21.7%. Net new business awards were $795.7 million, up 28.2%, for a net book-to-bill ratio of 1.13x, and backlog as of June 30, 2026 rose 4.9% to $3,014.2 million. For the six months ended June 30, 2026, revenue was $1,413.9 million, up 21.7% on a reported basis, and GAAP net income was $245.2 million, or $8.53 per diluted share. The company ended the quarter with $502.7 million in cash and cash equivalents, generated $162.0 million in operating cash flow in the second quarter, and repurchased 705,616 shares for $294.7 million, leaving $527.0 million under its share repurchase program. The company forecasts full-year 2026 revenue of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14.0% over 2025 revenue of $2.530 billion. It guides to GAAP net income of $494.0 million to $514.0 million, diluted EPS of $17.25 to $17.95, and EBITDA of $618.0 million to $642.0 million. Guidance assumes a tax rate of 19.0% to 19.5% and 28.6 million diluted weighted average shares, and excludes any share repurchases after June 30, 2026. Management will host a conference call on July 23, 2026 at 9:00 a.m. ET.

Jul 22, 2026
8-K
Leadership Changes

Medpace Holdings 8-K Report, Executive Changes (Jun 4, 2026)

Medpace Holdings, Inc. (MEDP) filed a Form 8-K under Item 5.02 reporting the appointment of Brad W. Hansman, age 43, to the position of Executive Vice President, Operations, effective June 1, 2026. In this role, Mr. Hansman will perform the functions of the Company's principal operating officer alongside Susan E. Burwig, who holds the title of Executive Vice President, Operations. Mr. Hansman has been with the Company since April 2011. He began in Finance & Accounting, held various Finance roles until July 2015, and since August 2015 has held operations leadership roles including Executive Director, Vice President, and Senior Vice President, overseeing study start-up, logistics, regulatory affairs, and medical writing. Before joining the Company, he worked as an Audit Supervisor at Joseph Decosimo & Company, LLC and as an auditor at Macy's, Inc. He holds a Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). The filing states he holds no public company directorships and has no family relationships with any director, director nominee, or executive officer. Compensation disclosed in the filing consists of an annual base salary of $492,250, eligibility for the short-term incentive plan with target cash bonus opportunities described in the Company's April 1, 2026 Proxy Statement, and eligibility for the long-term equity incentive plan at the discretion of the Compensation Committee. He also entered the Company's standard director and officer indemnification agreement.

Jun 4, 2026
8-K
Shareholder MattersCorporate ChangesExhibits & Filings

Medpace Holdings 8-K Report, Bylaw Amendment (May 19, 2026)

At its 2026 Annual Meeting on May 15, 2026, Medpace Holdings, Inc. stockholders approved two amendments to the Restated Certificate of Incorporation: removing supermajority voting requirements and removing the limitation on stockholders calling special meetings. The amendments became effective upon filing with the Delaware Secretary of State on May 18, 2026, and the company filed a Restated Certificate of Incorporation integrating them the same day. The Board approved conforming changes to the bylaws, under which one or more stockholders owning at least 25% of the voting power of outstanding shares may call a special meeting. Requesting stockholders must also meet notice, information, and other requirements, including having continuously owned at least 25% of the voting power for one year. Stockholders also elected five directors to serve until the 2027 Annual Meeting: Brian T. Carley, Femida H. Gwadry-Sridhar, Robert O. Kraft, August J. Troendle, and Dani S. Zander. They ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the advisory vote on named executive officer compensation, with 22,656,335 votes for and 1,737,558 against. In the advisory vote on say-on-pay frequency, the largest share of votes favored one year (23,989,262), and the Board determined that future advisory votes on executive compensation will be held annually. A non-binding stockholder proposal on giving shareholders the ability to call special meetings drew 8,306,071 votes for and 16,081,493 votes against, with 34,664 abstentions. The filing reports these results without describing the proposal's outcome beyond the vote counts.

May 19, 2026
8-K
Earnings & ResultsLeadership ChangesExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Apr 22, 2026)

Medpace Holdings, Inc. reported financial results for the three months ended March 31, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K filed April 22, 2026. Revenue rose 26.5% to $706.6 million from $558.6 million a year earlier. Net new business awards were $618.4 million, up 23.7% from $500.0 million, for a net book-to-bill ratio of 0.88x. Backlog as of March 31, 2026 was $2,929.2 million, up 2.9% from $2,846.0 million. GAAP net income was $123.9 million, or $4.28 per diluted share, compared with $114.6 million, or $3.67 per diluted share, in the prior-year quarter. EBITDA was $149.4 million, up 25.9%, with an EBITDA margin of 21.1%. For full-year 2026, the company forecasts revenue of $2.755 billion to $2.855 billion, GAAP net income of $487.0 million to $511.0 million, EBITDA of $605.0 million to $635.0 million, and diluted EPS of $16.68 to $17.50. The guidance assumes a 19.0% to 20.0% tax rate and 29.2 million diluted weighted average shares, and excludes any share repurchases after March 31, 2026. Cash and cash equivalents were $652.7 million at March 31, 2026, and operating cash flow for the quarter was $151.8 million. The filing also discloses that President Jesse Geiger notified the company on April 21, 2026, of his intent to resign and retire effective May 31, 2026, and that the departure is not the result of any disagreement with the company. Chief Executive Officer August Troendle will reassume the role of President until a successor is appointed.

Apr 22, 2026
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Feb 9, 2026)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported financial results for the fourth quarter and full year ended December 31, 2025, in a press release furnished as Exhibit 99.1 to this Form 8-K dated February 9, 2026. Fourth-quarter revenue rose 32.0% to $708.5 million, net new business awards were $736.6 million (a net book-to-bill ratio of 1.04x), and GAAP net income was $135.1 million, or $4.67 per diluted share. EBITDA grew 20.0% to $160.2 million, though its margin fell to 22.6% from 24.9% in the prior-year period. For the full year, revenue increased 20.0% to $2,530.2 million, GAAP net income was $451.1 million ($15.28 per diluted share), and EBITDA was $557.7 million. The company provided 2026 guidance calling for revenue of $2.755 billion to $2.855 billion, which the filing states represents growth of 8.9% to 12.8%. GAAP net income is forecast at $487.0 million to $511.0 million, diluted EPS at $16.68 to $17.50, and EBITDA at $605.0 million to $635.0 million. The guidance assumes a tax rate of 18.5% to 19.5% and 29.2 million diluted weighted average shares, and excludes any share repurchases after December 31, 2025. Capital returns were significant in 2025: the company repurchased 2,961,924 shares for $912.9 million, with no repurchases in the fourth quarter and $821.7 million remaining under its authorization at year-end. Cash and cash equivalents were $497.0 million at December 31, 2025, and backlog rose 4.3% to $3,027.2 million. Management will discuss the results on a conference call on February 10, 2026 at 9:00 a.m. ET.

Feb 9, 2026
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Oct 22, 2025)

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished a press release on October 22, 2025 (Exhibit 99.1) reporting results for the three and nine months ended September 30, 2025. Third-quarter revenue rose 23.7% to $659.9 million from $533.3 million, and net new business awards were $789.6 million, up 47.9%, for a net book-to-bill ratio of 1.20x. GAAP net income was $111.1 million, or $3.86 per diluted share, versus $96.4 million, or $3.01 per diluted share, a year earlier. EBITDA increased 24.9% to $148.4 million, with an EBITDA margin of 22.5%. Backlog as of September 30, 2025 was $3,000.6 million, up 2.5% from $2,927.4 million. For the nine months ended September 30, 2025, revenue was $1,821.8 million, up 15.9% on a reported basis, and GAAP net income was $316.0 million, or $10.64 per diluted share. Cash and cash equivalents fell to $285.4 million at September 30, 2025, from $669.4 million at December 31, 2024. During the nine months, the company repurchased 2,961,924 shares for $912.9 million, leaving $821.7 million remaining under its share repurchase program. For full-year 2025, the company forecasts revenue of $2.480 billion to $2.530 billion, GAAP net income of $431.0 million to $439.0 million, GAAP diluted EPS of $14.60 to $14.86, and EBITDA of $545.0 million to $555.0 million. The guidance excludes any share repurchases made after September 30, 2025. The company will host a conference call on October 23, 2025 at 9:00 a.m. ET.

Oct 22, 2025
8-K
Earnings & ResultsMaterial AgreementsExhibits & Filings

Medpace Holdings 8-K Report, Material Agreement (Jul 21, 2025)

Medpace Holdings, Inc. reported second-quarter 2025 revenue of $603.3 million, up 14.2% from $528.1 million a year earlier. GAAP net income was $90.3 million, or $3.10 per diluted share, compared with $88.4 million, or $2.75 per diluted share, in the prior-year quarter. Net income margin fell to 15.0% from 16.7%, while EBITDA rose 16.2% to $130.5 million, with an EBITDA margin of 21.6%. Net new business awards were $620.5 million, up 12.6%, for a net book-to-bill ratio of 1.03x. Backlog decreased 1.8% to $2,873.6 million as of June 30, 2025. The company raised its 2025 outlook in the form given: revenue of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. It also forecasts GAAP net income of $405.0 million to $428.0 million, EBITDA of $515.0 million to $545.0 million, and diluted EPS of $13.76 to $14.53. The guidance assumes a tax rate of 18.5% to 19.0% and 29.4 million diluted weighted average shares, and excludes any share repurchases after June 30, 2025. Capital allocation was heavy during the period. Medpace repurchased 1,754,264 shares in the second quarter at an average price of $295.59, for $518.5 million, and $908.4 million year to date. Cash and cash equivalents were $46.3 million at June 30, 2025, compared with $669.4 million at December 31, 2024, and $826.3 million remained under the share repurchase authorization. The filing also reports an amendment to the PNC Bank unsecured credit facility, under which the line of credit may be borrowed up to $10 million. The earnings release is furnished under Item 2.02 and is not deemed filed for Section 18 purposes.

Jul 21, 2025
8-K
Leadership ChangesShareholder MattersExhibits & Filings

Medpace Holdings 8-K Report, Executive Changes (May 16, 2025)

Medpace Holdings, Inc. held its 2025 Annual Meeting of Stockholders on May 16, 2025, where stockholders approved the 2016 Amended and Restated Incentive Award Plan (the Amended 2016 Plan). The Amended 2016 Plan did not increase the number of shares authorized for issuance under the prior 2016 Incentive Award Plan; its main change is extending the expiration date to February 6, 2035. The full plan is attached as Exhibit 10.1, and a description is referenced in the Company's Definitive Proxy Statement filed April 2, 2025. Stockholders elected August J. Troendle and Dani S. Zander as Class III Directors, each to serve until the 2026 Annual Meeting. Troendle received 21,156,998 votes for and 5,128,383 withheld, while Zander received 25,858,694 votes for and 426,687 withheld, with 1,533,208 broker non-votes for each nominee. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal 2025, with 27,200,285 votes for, 600,429 against, and 17,875 abstaining. In an advisory vote on named executive officer compensation, 24,918,234 votes were cast for, 1,340,033 against, and 27,114 abstaining. A non-binding advisory stockholder proposal regarding simple majority voting was approved with 18,210,462 votes for, 8,021,457 against, and 53,462 abstaining.

May 16, 2025
8-K
Earnings & ResultsMaterial AgreementsOther Events+1

Medpace Holdings 8-K Report, Material Agreement (Apr 21, 2025)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported first-quarter 2025 results on April 21, 2025. Revenue rose 9.3% to $558.6 million from $511.0 million, and GAAP net income was $114.6 million, or $3.67 per diluted share, versus $102.6 million, or $3.20 per diluted share, a year earlier. EBITDA increased 2.6% to $118.6 million, with the EBITDA margin falling to 21.2% from 22.6%. Net new business awards declined 18.8% to $500.0 million, resulting in a net book-to-bill ratio of 0.90x, and backlog decreased 2.1% to $2,846.0 million as of March 31, 2025. The company ended the quarter with $441.4 million in cash and cash equivalents and generated $125.8 million in operating cash flow. During the quarter it repurchased 1,193,011 shares at an average price of $326.78 for a total of $389.8 million. On April 17, 2025, the Board approved a $1.0 billion increase to the stock repurchase program, and $344.8 million remained under the program as of March 31, 2025. Separately, on April 18, 2025, the company's subsidiaries entered into Amendment No. 8 to the loan documents for its unsecured credit facility with PNC Bank, National Association, which increases the line of credit to up to $600 million, adjusts the interest rate and extends the revolving credit note's expiration to April 30, 2027. For 2025, the company forecasts revenue of $2.140 billion to $2.240 billion, representing growth of 1.5% to 6.2% over 2024 revenue of $2.109 billion. It guides to GAAP net income of $378.0 million to $402.0 million, EBITDA of $462.0 million to $492.0 million, and diluted EPS of $12.26 to $13.04. The guidance assumes a tax rate of 15.5% to 16.5%, interest income of $15.8 million and 30.8 million diluted shares, and it excludes any repurchases made after March 31, 2025.

Apr 21, 2025
8-K
Material AgreementsExhibits & Filings

Medpace Holdings 8-K Report, Material Agreement (Mar 31, 2025)

Medpace Holdings, Inc. (MEDP) disclosed in this Form 8-K filed March 31, 2025 that, on March 28, 2025, its wholly owned subsidiaries Medpace, Inc., as borrower, and Medpace IntermediateCo, Inc., as guarantor, entered into Amendment No. 7 to Loan Documents with PNC Bank, National Association, relating to the company's unsecured credit facility. The principal change in Amendment No. 7 is an extension of the expiration date of the revolving credit note to March 31, 2026. The filing describes the amendment as a material definitive agreement under Item 1.01 and attaches it as Exhibit 10.1, incorporated by reference. The filing does not include any other financial results, guidance, or operational disclosures. For investors, the filing is primarily a routine maintenance event for the company's revolving credit arrangement, keeping the unsecured facility available through March 31, 2026. The full terms of the amendment are set out in Exhibit 10.1, which the summary above does not reproduce.

Mar 31, 2025
8-K
Earnings & ResultsOther EventsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Feb 10, 2025)

Medpace Holdings, Inc. reported fourth-quarter 2024 revenue of $536.6 million, up 7.7% from $498.4 million a year earlier, and full-year 2024 revenue of $2.109 billion, up 11.8% from $1.886 billion. GAAP net income was $117.0 million ($3.67 per diluted share) for the quarter and $404.4 million ($12.63 per diluted share) for the year. EBITDA rose 39.3% to $133.5 million in the fourth quarter, with an EBITDA margin of 24.9%, and rose 32.5% to $480.2 million for the full year, with a 22.8% margin. Backlog increased 3.2% to $2,902.2 million at December 31, 2024. New business momentum softened in the quarter. Net new business awards were $529.7 million in the fourth quarter, down 13.8% from $614.7 million a year earlier, giving a net book-to-bill ratio of 0.99x. For the full year, awards totaled $2,230.0 million, a 1.06x book-to-bill ratio, compared with $2,356.7 million in 2023. Cash and cash equivalents were $669.4 million at year-end, and the company repurchased 527,160 shares in the fourth quarter for $174.2 million. For 2025, Medpace guided to revenue of $2.110 billion to $2.210 billion, which the filing describes as growth of 0.0% to 4.8%, GAAP net income of $378.0 million to $402.0 million, EBITDA of $462.0 million to $492.0 million, and diluted EPS of $11.93 to $12.69. The guidance assumes a tax rate of 18.0% to 19.0% and 31.7 million diluted shares, and excludes any repurchases after December 31, 2024. On February 6, 2025, the Board approved a $600 million increase to the stock repurchase program.

Feb 10, 2025
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Oct 21, 2024)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported third quarter 2024 results on October 21, 2024, via a press release furnished as Exhibit 99.1 under Item 2.02. Third quarter revenue rose 8.3% to $533.3 million from $492.5 million, while net new business awards were $533.7 million, down 12.7% from $611.5 million, giving a net book-to-bill ratio of 1.00x. Backlog increased 8.8% to $2,927.4 million as of September 30, 2024. Profitability improved substantially. GAAP net income for the quarter was $96.4 million, or $3.01 per diluted share, versus $70.6 million, or $2.22 per diluted share, a year earlier. EBITDA rose 31.7% to $118.8 million, with an EBITDA margin of 22.3% compared with 18.3% in the prior-year period. For the nine months ended September 30, 2024, revenue was $1,572.5 million, up 13.3%, and GAAP net income was $287.4 million, or $8.96 per diluted share. The company ended the quarter with $656.9 million in cash and cash equivalents and generated $149.1 million in operating cash flow in the third quarter. No share repurchases were made in the quarter, and $308.8 million remained under the authorized repurchase program. Full-year 2024 guidance calls for revenue of $2.090 billion to $2.130 billion, GAAP net income of $376.0 million to $388.0 million, and EBITDA of $450.0 million to $470.0 million.

Oct 21, 2024
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Jul 22, 2024)

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished a press release under Item 2.02 reporting its financial results for the three and six months ended June 30, 2024. Revenue for the second quarter of 2024 was $528.1 million, up 14.6% from $460.9 million a year earlier, with a backlog conversion rate of 18.2%. Net new business awards were $551.0 million, a 4.1% decrease from $574.8 million, producing a net book-to-bill ratio of 1.04x. GAAP net income rose to $88.4 million, or $2.75 per diluted share, from $61.1 million, or $1.93 per diluted share, and EBITDA increased 34.2% to $112.3 million, a 21.3% margin. For the first half of 2024, revenue was $1,039.1 million, up 16.1%, and GAAP net income was $190.9 million, or $5.96 per diluted share. Backlog as of June 30, 2024 increased 13.7% to $2,924.9 million. Cash and cash equivalents were $510.9 million at quarter end, and the company reported no share repurchases in the second quarter, with $308.8 million remaining under its authorized repurchase program. For full-year 2024, the company forecasts revenue of $2.125 billion to $2.175 billion, GAAP net income of $361.0 million to $383.0 million, EBITDA of $430.0 million to $460.0 million, and diluted EPS of $11.24 to $11.93. The guidance assumes a tax rate of 15.0% to 16.0%, interest income of $24.0 million, and 32.1 million diluted shares, and excludes any repurchases after June 30, 2024. A conference call is scheduled for 9:00 a.m. ET on July 23, 2024.

Jul 22, 2024
8-K
Leadership Changes

Medpace Holdings 8-K Report, Executive Changes (Jul 3, 2024)

Medpace Holdings, Inc. disclosed in this Form 8-K, filed July 3, 2024 under Item 5.02, that director Ashley M. Keating resigned from the Board of Directors effective June 30, 2024. The filing states her resignation did not result from any disagreement with the Company on matters relating to its operations, policies or practices. The Board, following a recommendation from its independent directors, unanimously elected Dr. Dani S. Zander to fill the resulting Class III director vacancy, effective July 1, 2024, with her term running until the 2025 Annual Meeting of Stockholders. Dr. Zander was also appointed to the Nominating and Governance Committee effective the same date. She is the MacKenzie Chair of the Department of Pathology and Laboratory Medicine at the University of Cincinnati and Chief of Pathology and Laboratory Medicine for UC Health, and the filing describes her background in lung pathology, cytopathology and academic pathology leadership. Under the Company's standard non-employee director compensation program, Dr. Zander received on July 1, 2024 an option to purchase 824 shares of common stock at an exercise price equal to that day's closing price, with a seven-year term. The Company also entered into its standard director and officer indemnification agreement with her.

Jul 3, 2024
8-K
Shareholder MattersCorporate ChangesExhibits & Filings

Medpace Holdings 8-K Report, Bylaw Amendment (May 21, 2024)

At its 2024 Annual Meeting of Stockholders, held May 17, 2024, Medpace Holdings, Inc. stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to begin phasing out the Company's classified Board of Directors. Directors up for election at and after the 2025 Annual Meeting will be elected annually. The amendment became effective upon filing with the Delaware Secretary of State on May 17, 2024, and the Company then filed a new Restated Certificate of Incorporation the same day. The Board also approved conforming amendments to the Amended and Restated Bylaws to remove the requirement that the Board be divided into three classes. Stockholders re-elected Class II directors Fred B. Davenport, Jr. and Cornelius P. McCarthy III, each to serve until the 2027 Annual Meeting. Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The advisory vote on named executive officer compensation was approved, with 26,373,187 votes for and 701,630 against. The filing's other stockholder votes were also approved. The declassification amendment received 27,081,976 votes for and 4,407 against. The filing reports these results and incorporates the full amended governing documents, Exhibits 3.1 and 3.2, by reference.

May 21, 2024
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Apr 22, 2024)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported first quarter 2024 results on April 22, 2024, as furnished under Item 2.02 of this Form 8-K (press release attached as Exhibit 99.1). Revenue rose 17.7% to $511.0 million from $434.1 million a year earlier, and backlog increased 18.2% to $2,907.1 million. Net new business awards were $615.6 million, up 10.8%, for a net book-to-bill ratio of 1.20x. Profitability improved meaningfully. GAAP net income was $102.6 million, or $3.20 per diluted share, versus $72.9 million, or $2.27 per diluted share, in the prior-year quarter, with net income margin of 20.1% compared to 16.8%. EBITDA increased 24.6% to $115.7 million, a 22.6% margin. Cash and cash equivalents were $407.0 million at March 31, 2024, and operating cash flow was $152.7 million for the quarter. No share repurchases were made in the quarter, and $308.8 million remained under the authorized repurchase program. For full-year 2024, the company forecasts revenue of $2.150 billion to $2.200 billion, representing growth of 14.0% to 16.7% over 2023 revenue of $1.886 billion. GAAP net income is forecast at $347.0 million to $369.0 million, diluted EPS (GAAP) at $10.79 to $11.47, and EBITDA at $415.0 million to $445.0 million. The guidance assumes a 15.0% to 16.0% tax rate and 32.1 million diluted shares outstanding, and excludes any share repurchases after March 31, 2024.

Apr 22, 2024
8-K
Material AgreementsExhibits & Filings

Medpace Holdings 8-K Report, Material Agreement (Mar 29, 2024)

Medpace Holdings, Inc. (MEDP) reported in an 8-K filed March 29, 2024 that on March 28, 2024, its wholly owned subsidiaries Medpace, Inc. (as borrower) and Medpace IntermediateCo, Inc. (as guarantor) entered into Amendment No. 6 to Loan Documents with PNC Bank, National Association, relating to the Company's unsecured credit facility. According to the filing, Amendment No. 6 changes the aggregate principal amount that may be borrowed under the facility's line of credit to up to $10 million and extends the expiration date of the revolving credit note to March 31, 2025. The filing states that the full terms are qualified by reference to the amendment, which is filed as Exhibit 10.1. The filing is a limited material-agreement disclosure under Item 1.01. It contains no financial results, operating metrics, or guidance, so the amendment's main investor-relevant points are the borrowing capacity and the extended maturity of the revolving credit note.

Mar 29, 2024
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Feb 12, 2024)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported fourth-quarter and full-year 2023 results in a press release dated February 12, 2024, furnished as Exhibit 99.1 to this Form 8-K under Item 2.02. For the fourth quarter, revenue increased 26.5% to $498.4 million, net new business awards were $614.7 million (a 1.23x net book-to-bill ratio), and GAAP net income was $78.3 million, or $2.46 per diluted share. EBITDA rose 19.2% to $95.8 million. For the full year 2023, revenue increased 29.2% to $1,885.8 million, GAAP net income was $282.8 million, or $8.88 per diluted share, and EBITDA was $362.5 million. Backlog as of December 31, 2023 increased 20.2% to $2,813.0 million. The company issued 2024 guidance calling for revenue of $2.150 billion to $2.200 billion, representing growth of 14.0% to 16.7% over 2023 revenue. It expects GAAP net income of $326.0 million to $348.0 million, diluted EPS of $10.18 to $10.87, and EBITDA of $400.0 million to $430.0 million. The guidance assumes a tax rate of 16.0% to 17.0%, interest income of $18.4 million, and 32.0 million diluted shares, and excludes any future share repurchases. On the balance sheet, cash and cash equivalents were $245.4 million at December 31, 2023, up from $28.3 million a year earlier, and operating cash flow for the full year was $433.4 million. The company repurchased 781,068 shares for $144.0 million in 2023 and had $308.8 million remaining under its repurchase program. The filing also notes a conference call on February 13, 2024 at 9:00 a.m. ET.

Feb 12, 2024
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Oct 23, 2023)

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished a press release on October 23, 2023 reporting results for the three and nine months ended September 30, 2023. Third-quarter revenue was $492.5 million, up 28.3% from $383.7 million a year earlier, with a backlog conversion rate of 19.1%. Net new business awards were $611.5 million, up 29.9%, for a net book-to-bill ratio of 1.24x. GAAP net income was $70.6 million, or $2.22 per diluted share, compared with $66.0 million, or $2.05 per diluted share, in the prior-year quarter. EBITDA was $90.2 million, up 1.0%, with an EBITDA margin of 18.3%, down from 23.3% a year earlier. For the nine months ended September 30, 2023, revenue was $1,387.4 million, up 30.2% on a reported basis, and GAAP net income was $204.5 million, or $6.42 per diluted share. Backlog as of September 30, 2023 was $2,689.5 million, up 20.3%. Cash and cash equivalents were $95.2 million at quarter end, operating cash flow for the third quarter was $114.4 million, and the company paid off its remaining outstanding debt during the quarter. Management guided full-year 2023 revenue to $1.870 billion to $1.890 billion, GAAP net income to $272.0 million to $276.0 million, and diluted EPS to $8.54 to $8.66. For 2024, it forecast revenue of $2.150 billion to $2.200 billion and EBITDA of $390.0 million to $415.0 million. The results were furnished under Item 2.02 and are not deemed filed under Section 18 of the Exchange Act.

Oct 23, 2023
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Jul 24, 2023)

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished an Item 2.02 Form 8-K on July 24, 2023, attaching a press release reporting its results for the three and six months ended June 30, 2023. For the second quarter, revenue rose 31.2% to $460.9 million from $351.2 million, and backlog grew 18.6% to $2,571.9 million. Net new business awards were $574.8 million, a 27.6% increase, producing a net book-to-bill ratio of 1.25x. GAAP net income was $61.1 million, or $1.93 per diluted share, compared with $49.4 million, or $1.46 per diluted share, a year earlier. EBITDA rose 22.8% to $83.6 million, with an EBITDA margin of 18.1%. For the first six months of 2023, revenue was $894.9 million and GAAP net income was $134.0 million, or $4.20 per diluted share. Year-to-date EBITDA was $176.5 million, or 19.7% of revenue. The company repurchased 126,281 shares for $23.9 million in the second quarter and had $308.8 million remaining under its share repurchase program at June 30, 2023. Cash and cash equivalents were $39.1 million and short-term debt was $55.0 million at quarter end. For full-year 2023, Medpace forecasts revenue of $1.840 billion to $1.880 billion, GAAP net income of $256.0 million to $271.0 million, EBITDA of $340.0 million to $358.0 million, and diluted EPS of $8.04 to $8.50. The guidance assumes a tax rate of 17.5% to 18.5% and excludes the effect of any share repurchases after June 30, 2023. The press release is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act.

Jul 24, 2023
8-K
Shareholder Matters

Medpace Holdings 8-K Report, Shareholder Vote Results (May 19, 2023)

Medpace Holdings, Inc. held its 2023 Annual Meeting of Stockholders on May 19, 2023. Stockholders elected Brian T. Carley, Femida H. Gwadry-Sridhar, and Robert O. Kraft as Class I Directors, each to serve until the 2026 Annual Meeting. Gwadry-Sridhar received the most support at 27,027,873 votes for and 782,923 withheld. Carley received 15,744,076 votes for and 12,066,720 withheld, and Kraft received 15,166,913 votes for and 12,643,883 withheld. Each director nominee also had 1,172,784 broker non-votes. Stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote was 28,343,821 for, 630,701 against, and 9,058 abstentions, with no broker non-votes reported. Stockholders also approved, on an advisory basis, the compensation of the Company's Named Executive Officers. The vote was 26,073,214 for, 1,715,903 against, and 21,679 abstentions, with 1,172,784 broker non-votes. The filing reports no other items under Items 5.07(c) or 5.07(d).

May 19, 2023
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Apr 24, 2023)

Medpace Holdings, Inc. filed this Form 8-K under Item 2.02 (Results of Operations and Financial Condition) on April 24, 2023, furnishing a press release announcing financial results for the three months ended March 31, 2023. The filing is furnished rather than filed, so it is not subject to Section 18 liability. In the quarter, revenue, net was $434.1 million, up 31.2% from $330.9 million a year earlier, and net new business awards were $555.8 million, up 31.4% from $423.0 million, producing a net book-to-bill ratio of 1.28x. Backlog rose 17.8% to $2,460.1 million as of March 31, 2023. GAAP net income was $72.9 million, or $2.27 per diluted share, compared with $61.3 million, or $1.69 per diluted share, in the prior-year quarter. Net income margin declined to 16.8% from 18.5%, while EBITDA rose 31.9% to $92.8 million, with EBITDA margin of 21.4% versus 21.3% a year earlier. Cash flow from operations was $80.1 million, and the company repurchased 654,787 shares for $120.1 million, leaving $332.7 million under its authorized repurchase program. Short-term debt increased to $115.0 million from $50.0 million at December 31, 2022. For full-year 2023, the company forecast revenue of $1.745 billion to $1.805 billion, GAAP net income of $250.0 million to $269.0 million, EBITDA of $335.0 million to $355.0 million, and diluted EPS of $7.81 to $8.40. Guidance assumes a tax rate of 17.5% to 18.5% and excludes any share repurchases made after March 31, 2023.

Apr 24, 2023
8-K
Material AgreementsExhibits & Filings

Medpace Holdings 8-K Report, Material Agreement (Mar 31, 2023)

Medpace Holdings, Inc. (MEDP) reported on a Form 8-K dated March 31, 2023 that it entered into Amendment No. 5 to Loan Documents with PNC Bank, National Association, in connection with its unsecured credit facility. The agreement was executed through its wholly owned subsidiaries, Medpace, Inc., as borrower, and Medpace IntermediateCo, Inc., as guarantor. The amendment changes the aggregate principal amount that may be borrowed under the facility's line of credit to up to $150 million. It also adjusts the interest rate and fee charged on the credit facility and extends the expiration date of the revolving credit note to March 29, 2024. The filing is limited to this material agreement and its related exhibit. The full terms of Amendment No. 5 are filed as Exhibit 10.1, and the filing also includes the Cover Page Interactive Data File embedded within the Inline XBRL document.

Mar 31, 2023
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Feb 13, 2023)

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished an 8-K under Item 2.02 on February 13, 2023, announcing its financial results for the three and twelve months ended December 31, 2022. Fourth-quarter 2022 revenue rose 27.7% to $394.1 million from $308.6 million, and net new business awards were $485.1 million, for a net book-to-bill ratio of 1.23x. GAAP net income was $68.7 million, or $2.12 per diluted share, versus $50.0 million, or $1.32 per diluted share, a year earlier. EBITDA increased 30.9% to $80.4 million, a 20.4% margin. For full year 2022, revenue increased 27.8% to $1,460.0 million and GAAP net income was $245.4 million, or $7.28 per diluted share. Full-year EBITDA rose 38.1% to $308.1 million, or 21.1% of revenue. Backlog as of December 31, 2022 increased 17.2% to $2,339.6 million. The company repurchased approximately 5.7 million shares for $847.7 million during 2022 and had $452.8 million remaining under its share repurchase program. Cash and cash equivalents were $28.3 million at year-end, down from $461.3 million, and short-term debt was $50.0 million. For 2023, Medpace guided to revenue of $1.690 billion to $1.750 billion, GAAP net income of $245.0 million to $265.0 million, EBITDA of $325.0 million to $350.0 million, and diluted GAAP EPS of $7.53 to $8.14, assuming a 17.5% to 18.5% tax rate and no future share repurchases after December 31, 2022. The accompanying press release is furnished, not filed, under Item 2.02.

Feb 13, 2023
8-K
Leadership Changes

Medpace Holdings 8-K Report, Executive Changes (Jan 18, 2023)

Medpace Holdings, Inc. filed this Form 8-K under Item 5.02 to report that its Board of Directors, on January 16, 2023, unanimously approved the election of Dr. Femida H. Gwadry-Sridhar to fill the Class I director vacancy, effective that same day. Following a recommendation from the independent directors, she will serve as a Class I director until the 2023 Annual Meeting of Stockholders, and she is expected to be appointed to the Nominating and Governance Committee. Dr. Gwadry-Sridhar is the Founder and Chief Executive Officer of Pulse Infoframe Inc., a privately held real-world evidence generation platform company she has led since 2011. The filing describes her academic background, including appointments at Western University and as a visiting professor at the University of Southern California, along with more than 220 publications and recognition as a career scientist and lifetime fellow of the Canadian Institute of Health Research. Under the Company's standard non-employee director compensation program, she received on January 16, 2023 an option to purchase 573 shares of common stock at an exercise price equal to the January 13, 2023 closing price, the last trading day before her election date. The option has a seven-year term, and the Company has entered into its standard director and officer indemnification agreement with her.

Jan 18, 2023
8-K
Leadership Changes

Medpace Holdings 8-K Report, Executive Changes (Jan 3, 2023)

Medpace Holdings, Inc. filed this Current Report on Form 8-K with a date of report of December 31, 2022, disclosing a single board change under Item 5.02. Thomas C. King notified the company on December 31, 2022 of his resignation from its Board of Directors, effective that same day. The filing states that his resignation did not result from any disagreement with the company on any matter relating to its operations, policies or practices. The report was signed by Stephen P. Ewald, General Counsel and Corporate Secretary, on January 3, 2023. The filing contains no financial results, guidance, or operational metrics. Its significance for investors is limited to governance: a director departure effective at year-end, with no stated disagreement behind it. The filing does not state a replacement director or any change to board committee composition. The registrant is listed on the Nasdaq Global Select Market under the symbol MEDP, and its principal executive offices are in Cincinnati, Ohio.

Jan 3, 2023
8-K
Earnings & ResultsOther EventsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Oct 24, 2022)

Medpace Holdings, Inc. reported financial results for the third quarter and nine months ended September 30, 2022, in a press release furnished as Exhibit 99.1. Third-quarter revenue rose 29.8% to $383.7 million from $295.6 million, and GAAP net income was $66.0 million, or $2.05 per diluted share, versus $48.6 million, or $1.29 per diluted share, a year earlier. EBITDA increased 48.5% to $89.3 million, with an EBITDA margin of 23.3%. Backlog grew 20.9% to $2.2 billion, and net new business awards were $470.9 million, a net book-to-bill ratio of 1.23x. For the nine months, revenue was $1,065.9 million, up 27.8% on a reported basis, and GAAP net income was $176.7 million, or $5.18 per diluted share. The company repurchased $800.7 million of common stock in the first nine months, and its cash and cash equivalents fell to $31.0 million at September 30, 2022, from $461.3 million at December 31, 2021. Short-term debt was $139.7 million. On October 21, 2022, the Board authorized share repurchases of up to $500 million. The company raised no new guidance beyond the figures given. For full-year 2022, it forecasts revenue of $1.440 billion to $1.460 billion, GAAP net income of $232.0 million to $236.0 million, and diluted EPS of $6.88 to $7.00. For 2023, it forecasts revenue of $1.680 billion to $1.740 billion and EBITDA of $325.0 million to $350.0 million.

Oct 24, 2022
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Jul 25, 2022)

Medpace Holdings, Inc. reported second quarter 2022 results in a press release furnished under Item 2.02 of this Form 8-K. Revenue rose 26.2% to $351.2 million from $278.3 million in the prior-year quarter, and on a constant currency organic basis revenue increased 27.7%. Net new business awards were $450.6 million, up 16.3% from $387.6 million, for a net book-to-bill ratio of 1.28x. Backlog grew 24.4% to $2.2 billion as of June 30, 2022. GAAP net income was $49.4 million, or $1.46 per diluted share, compared with $39.9 million, or $1.06 per diluted share, a year earlier. EBITDA increased 42.0% to $68.1 million, a 19.4% margin, versus $47.9 million in the prior-year quarter. The company also reported a sharp change in its balance sheet during the quarter. Cash and cash equivalents were $42.6 million at June 30, 2022, compared with $461.3 million at December 31, 2021. Short-term debt was $249.7 million. Medpace repurchased approximately 2.7 million shares at an average price of $137.86 per share, totaling $374.6 million in the second quarter, and stated that it has completed all authorized share repurchases under its repurchase program. Operating cash flow in the second quarter was $96.6 million. For full-year 2022, Medpace forecast revenue of $1.405 billion to $1.435 billion, representing growth of 23.0% to 25.6% over 2021 revenue of $1.142 billion, GAAP net income of $205.0 million to $215.0 million, and EBITDA of $268.0 million to $280.0 million. Diluted EPS is forecast at $6.07 to $6.36, based on 33.8 million diluted weighted-average shares and a tax rate of 14.5% to 15.5%. The guidance does not reflect any share repurchases after June 30, 2022. The company expects a foreign exchange revenue headwind of approximately $4.0 million and an EBITDA tailwind of approximately $3.0 million.

Jul 25, 2022
8-K
Other Events

Medpace Holdings 8-K Report, Corporate Update (Jun 10, 2022)

Medpace Holdings, Inc. filed this Form 8-K on June 10, 2022 under Item 8.01 (Other Events) to disclose a change to its share repurchase program. As of June 10, 2022, the Board of Directors approved an increase of $50 million to the Company's existing stock repurchase program. The filing states that the timing, price and volume of repurchases will depend on market conditions, applicable securities laws and other factors. Repurchases may be made from time to time through solicited or unsolicited open-market transactions, privately negotiated transactions, or pursuant to a Rule 10b5-1 plan. The filing also notes that the program may be discontinued or amended at any time without notice. The filing does not state the program's remaining authorization or any repurchases made to date.

Jun 10, 2022
8-K
Other Events

Medpace Holdings 8-K Report, Corporate Update (May 26, 2022)

Medpace Holdings, Inc. (MEDP) filed a Form 8-K on May 26, 2022 under Item 8.01 (Other Events) to disclose two capital allocation updates. As of May 25, 2022, the Board of Directors approved a $60 million increase to the Company's stock repurchase program. The filing states that repurchases will depend on market conditions, securities laws and other factors, may be made in the open market, in privately negotiated transactions, or under a Rule 10b5-1 plan, and that the program may be discontinued or amended at any time without notice. The filing also reports repurchase activity since April 22, 2022. Between that date and May 25, 2022, the Company repurchased 1,597,007 shares of common stock for treasury, which the filing says resulted in a decrease of approximately 5% of outstanding shares measured from April 22, 2022. As of May 25, 2022, the Company had 32,065,701 shares of common stock outstanding. For investors, the key takeaways are the expanded buyback authorization and the recent pace of share retirement through treasury purchases, which reduces the share count. The filing contains no financial results, guidance, or operational updates.

May 26, 2022
8-K
Shareholder Matters

Medpace Holdings 8-K Report, Shareholder Vote Results (May 20, 2022)

On May 20, 2022, Medpace Holdings, Inc. held its 2022 Annual Meeting of Stockholders. Stockholders elected two Class III directors, August J. Troendle and Ashley M. Keating, to serve until the 2025 Annual Meeting. Troendle received 23,374,363 votes for and 7,211,789 withheld. Keating received 12,863,441 votes for and 17,722,711 withheld, so more shares were withheld than voted for him. The filing reports that both nominees were elected. Stockholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 30,576,845 votes for, 676,331 against, and 13,308 abstaining. In a non-binding advisory vote, stockholders approved the compensation of the Company's Named Executive Officers, with 22,093,994 votes for, 8,458,621 against, and 33,537 abstaining. The filing lists 680,332 broker non-votes on the director and say-on-pay proposals. The filing reports no other matters submitted to a vote. Its key investor takeaways are the board election, the auditor ratification, and the say-on-pay approval, with the notably high withheld count for Keating as the main point to watch.

May 20, 2022
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Apr 25, 2022)

Medpace Holdings, Inc. furnished a press release dated April 25, 2022 (Exhibit 99.1) reporting results for the three months ended March 31, 2022. Revenue rose 27.3% to $330.9 million from $260.0 million a year earlier, and constant-currency organic revenue rose 28.1%. GAAP net income was $61.3 million, or $1.69 per diluted share, versus $43.3 million, or $1.14 per diluted share, in the prior-year quarter. EBITDA increased 31.3% to $70.4 million, with an EBITDA margin of 21.3%. Net new business awards were $423.0 million, a net book-to-bill ratio of 1.28x, and backlog grew 28.0% to $2.1 billion. The company repurchased about 2.7 million shares for a total of $425.9 million during the quarter, and its Board approved an additional $200 million for the stock repurchase program on March 16, 2022. Cash and cash equivalents fell to $82.8 million at March 31, 2022, from $461.3 million at December 31, 2021, and $264.6 million remained under the repurchase authorization at quarter end. Operating cash flow was $46.3 million. For full-year 2022, Medpace forecasts revenue of $1.400 billion to $1.460 billion, representing growth of 22.6% to 27.8% over 2021 revenue of $1.142 billion. It guides GAAP net income of $204.0 million to $216.0 million, EBITDA of $262.0 million to $278.0 million, and diluted EPS of $5.72 to $6.06, assuming a 13.5% to 14.5% tax rate and 35.6 million fully diluted shares. The guidance does not reflect repurchases made after March 31, 2022.

Apr 25, 2022
8-K
Material AgreementsOther EventsExhibits & Filings

Medpace Holdings 8-K Report, Material Agreement (Mar 16, 2022)

Medpace Holdings, Inc., a Delaware corporation, reported on its March 16, 2022 Form 8-K two main actions. First, on March 15, 2022, its wholly owned subsidiary Medpace, Inc., as borrower, with Medpace IntermediateCo, Inc., as guarantor, entered into Amendment No. 4 to Loan Documents with PNC Bank, National Association, relating to the company's unsecured credit facility. The amendment increases the aggregate principal amount that may be borrowed under the line of credit to up to $250 million and updates provisions related to anti-money laundering and international trade law compliance. The full amendment is filed as Exhibit 10.1. Second, the Board of Directors approved an increase of $200 million to the company's stock repurchase program as of March 16, 2022. Repurchases may be made in the open market, in privately negotiated transactions, or under a Rule 10b5-1 plan, and the program may be discontinued or amended at any time without notice. Between February 11, 2022 and March 14, 2022, the company repurchased 1,782,136 shares for treasury, which the filing says decreased outstanding shares by approximately 5%. As of March 14, 2022, Medpace had 33,723,904 shares of common stock outstanding. For investors, the filing points to expanded borrowing capacity and a larger buyback authorization, with recent repurchases already reducing the share count.

Mar 16, 2022
8-K
Earnings & ResultsOther EventsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Feb 14, 2022)

Medpace Holdings, Inc. reported fourth-quarter 2021 revenue of $308.6 million, up 18.8% from $259.7 million a year earlier, and full-year 2021 revenue of $1,142.4 million, up 23.4%. GAAP net income was $50.0 million ($1.32 per diluted share) for the fourth quarter, compared with $50.9 million ($1.35 per diluted share) in the prior-year period. For the full year, GAAP net income rose to $181.8 million ($4.81 per diluted share) from $145.4 million ($3.84 per diluted share). Full-year EBITDA was $223.1 million, up 18.8%. The company reported a backlog of $1,997.1 million at December 31, 2021, up 29.5%, and full-year net new business awards of $1,610.4 million, a net book-to-bill ratio of 1.41x. The company ended 2021 with $461.3 million in cash and cash equivalents and generated $70.9 million in operating cash flow during the fourth quarter. It did not repurchase shares in the fourth quarter and had $190.5 million remaining under its share repurchase program at quarter end. As of February 10, 2022, the Board approved a $300 million increase to the program. The filing states that repurchases may be made in the open market, in privately negotiated transactions, or under a Rule 10b5-1 plan, and that the program may be discontinued or amended at any time. For 2022, the company forecasts revenue of $1.400 billion to $1.460 billion, GAAP net income of $204.0 million to $216.0 million, EBITDA of $262.0 million to $278.0 million, and diluted GAAP EPS of $5.35 to $5.67. The guidance assumes a tax rate of 13.5% to 14.5% and does not reflect share repurchases made after December 31, 2021. The full press release, furnished as Exhibit 99.1, is incorporated by reference.

Feb 14, 2022
8-K
Material AgreementsExhibits & Filings

Medpace Holdings 8-K Report, Material Agreement (Dec 29, 2021)

Medpace Holdings, Inc. filed this Form 8-K on December 29, 2021 to report a material amendment to its credit arrangements. On December 27, 2021, its wholly owned subsidiaries Medpace, Inc. (as borrower) and Medpace IntermediateCo, Inc. (as guarantor) entered into Amendment No. 3 to Loan Documents with PNC Bank, National Association. The loan documents govern an unsecured credit facility with an aggregate principal amount of up to $50 million. Amendment No. 3 extends the expiration date of the revolving credit note to March 31, 2023. It also adds provisions for alternative interest rates arising from global reference rate initiatives, and it removes the ability to obtain advances in any currency other than U.S. Dollars. The filing states that the description of the amendment is qualified in its entirety by the full text, which is filed as Exhibit 10.1. For investors, the filing is primarily a routine credit facility update: it preserves the existing $50 million unsecured revolver, extends its maturity, and aligns its interest rate terms with the transition away from legacy reference rates. The filing does not report financial results, guidance, or changes to the company's operations.

Dec 29, 2021
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Oct 25, 2021)

Medpace Holdings, Inc. furnished a press release on October 25, 2021 reporting results for the three and nine months ended September 30, 2021. For the third quarter, revenue rose 28.3% to $295.6 million, backlog grew 29.0% to $1.8 billion, and net new business awards were $408.0 million, a net book-to-bill ratio of 1.38x. GAAP net income was $48.6 million, or $1.29 per diluted share, compared with $41.5 million, or $1.09 per diluted share, a year earlier. EBITDA rose 15.7% to $60.1 million, though EBITDA margin was 20.3% versus 22.5% in the prior-year period. For full-year 2021, the company forecasts revenue of $1.135 billion to $1.145 billion, GAAP net income of $176.0 million to $180.0 million, diluted EPS of $4.66 to $4.77, and EBITDA of $216.0 million to $222.0 million. It also provided initial 2022 guidance of $1.400 billion to $1.460 billion in revenue and $262.0 million to $278.0 million in EBITDA. Cash and cash equivalents were $398.4 million at September 30, 2021, and operating cash flow for the third quarter was $72.4 million. The company repurchased about 35,000 shares for $5.9 million in the quarter and had $190.5 million remaining under its repurchase authorization. The results are presented in the furnished press release, which is not deemed filed under Section 18 of the Exchange Act. The company also said it would host a conference call on October 26, 2021 at 9:00 a.m. ET to discuss the quarter.

Oct 25, 2021
8-K
Leadership ChangesExhibits & Filings

Medpace Holdings 8-K Report, Executive Changes (Jul 26, 2021)

Medpace Holdings, Inc. (Nasdaq: MEDP) announced on July 26, 2021 a senior leadership change effective August 1, 2021. Jesse J. Geiger, who joined Medpace in October 2007 as Corporate Controller and has served as Chief Financial Officer since March 2011 and Chief Operating Officer, Laboratory Operations since November 2014, was appointed to the newly created position of President. Kevin M. Brady, who has served as Executive Director, Finance and Treasurer since November 2018 and Treasurer since February 2019, was appointed Chief Financial Officer, succeeding Geiger. Geiger will continue to report to August J. Troendle, who will remain Chairman of the Board and Chief Executive Officer. The company stated that the new President role will allow Troendle to continue focusing on the overall long-term strategic direction of the company. Brady's annual base salary as CFO will be $340,000, and he will be eligible for the short-term incentive compensation plan, with target cash bonus opportunities expressed as a percentage of base salary, and the long-term equity incentive compensation plan. Brady and the company expect to enter into the company's standard indemnification agreement used with other executive officers. The filing describes the changes as a promotion and a restructuring of senior roles rather than a change in strategy. Investors should note that the filing gives no new financial results; it reports only personnel and compensation details, with the company's approximately 4,100 employees across 40 countries as of June 30, 2021 provided for context.

Jul 26, 2021
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Jul 26, 2021)

Medpace Holdings, Inc. filed this Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) on July 26, 2021, furnishing a press release announcing financial results for the three and six months ended June 30, 2021. The information is furnished rather than filed for purposes of Section 18 of the Exchange Act. The press release reports second-quarter 2021 revenue of $278.3 million, up 35.8% from $205.0 million a year earlier, with a backlog conversion rate of 17.1%. Net new business awards were $387.6 million, up 52.5% from $254.1 million, for a net book-to-bill ratio of 1.39x. GAAP net income was $39.9 million, or $1.06 per diluted share, compared with $24.1 million, or $0.64 per diluted share, in the prior-year quarter. EBITDA was $47.9 million, up 36.9%, with an EBITDA margin of 17.2%. Backlog as of June 30, 2021 was $1.7 billion, up 29.8% from $1.3 billion a year earlier. Cash and cash equivalents were $339.0 million at June 30, 2021, and operating cash flow was $62.8 million in the second quarter. The company repurchased approximately 0.34 million shares for $56.1 million during the quarter and had $196.4 million remaining under its share repurchase program. For full-year 2021, Medpace forecasts revenue of $1.110 billion to $1.150 billion, representing growth of 19.9% to 24.2% over 2020 revenue of $925.9 million. Guidance also calls for GAAP net income of $162.5 million to $169.5 million, EBITDA of $205.0 million to $215.0 million, and diluted EPS of $4.31 to $4.50, assuming a tax rate of 11.0% to 12.0% and excluding any share repurchases after June 30, 2021. A conference call is scheduled for 9:00 a.m. ET on July 27, 2021.

Jul 26, 2021
8-K
Other Events

Medpace Holdings 8-K Report, Corporate Update (Jul 23, 2021)

Medpace Holdings, Inc., a Delaware corporation, filed this Form 8-K on July 23, 2021 under Item 8.01 (Other Events) to disclose that its Board of Directors established a Nominating and Governance Committee on July 22, 2021. The filing describes the committee's purpose: identifying qualified Board candidates consistent with the Corporate Governance Guidelines, recommending director nominees for the annual meeting and interim vacancies, recommending governance matters including periodic review of the Guidelines, and recommending director nominees for each Board committee. The committee is composed of six current Board members: Brian T. Carley, Fred B. Davenport, Jr., Ashley M. Keating, Thomas C. King, Robert O. Kraft, and Cornelius P. McCarthy III. The filing states that each member qualifies as independent under the listing requirements of the NASDAQ Global Select Market. The committee charter will be posted at www.medpace.com. The filing contains no financial results, guidance, or operational metrics. Its significance for investors is primarily one of corporate governance: a dedicated independent committee now oversees Board composition and governance practices.

Jul 23, 2021
8-K
Other Events

Medpace Holdings 8-K Report, Corporate Update (Jun 11, 2021)

Medpace Holdings, Inc., a Delaware corporation, reported in this Current Report on Form 8-K filed June 11, 2021 that its Board of Directors approved an increase of $150 million to the Company's stock repurchase program, effective as of June 11, 2021. The filing is brief and reports this single event under Item 8.01 (Other Events). The filing states that repurchases will be made based on market conditions, relevant securities laws and other factors, and may be executed through solicited or unsolicited open-market transactions, privately negotiated transactions, or pursuant to a Rule 10b5-1 plan. The timing, price and volume of repurchases are left to those considerations. The filing also notes that the repurchase program may be discontinued or amended at any time without notice. No other financial results, guidance, or operating data are contained in this filing.

Jun 11, 2021
8-K
Shareholder Matters

Medpace Holdings 8-K Report, Shareholder Vote Results (May 14, 2021)

On May 14, 2021, Medpace Holdings, Inc. held its 2021 Annual Meeting of Stockholders, where shareholders voted on three proposals. Cornelius P. McCarthy III and Fred B. Davenport, Jr. were elected as Class II Directors to serve until the 2024 Annual Meeting. McCarthy received 20,068,499 votes for and 12,342,894 withheld, while Davenport received 13,611,160 votes for and 18,800,233 withheld. Broker non-votes were 828,001 for each director. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, with 31,816,172 votes for, 1,408,143 against, 15,079 abstentions, and no broker non-votes. In a non-binding advisory vote, stockholders approved the compensation of the Company's Named Executive Officers, with 16,348,309 votes for, 16,015,301 against, 47,783 abstentions, and 828,001 broker non-votes. The filing reports no other matters submitted to a vote. The results cover board composition, auditor ratification, and say-on-pay, the three standard annual meeting items.

May 14, 2021
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Apr 26, 2021)

Medpace Holdings, Inc. furnished a press release under Item 2.02 reporting its financial results for the three months ended March 31, 2021. Revenue, net was $260.0 million, up 12.6% from $230.9 million in the prior-year period, with constant currency organic revenue growth of 11.6%. Net new business awards were $356.2 million, up 44.2% from $246.9 million, for a net book-to-bill ratio of 1.37x, and backlog grew 26.1% to $1.6 billion. GAAP net income was $43.3 million, or $1.14 per diluted share, versus $29.0 million, or $0.76 per diluted share, a year earlier. EBITDA rose 32.1% to $53.6 million, a 20.6% margin. The company provided full-year 2021 guidance calling for revenue of $1.090 billion to $1.150 billion, GAAP net income of $160.6 million to $167.6 million, EBITDA of $205.0 million to $215.0 million, and diluted GAAP EPS of $4.24 to $4.42, assuming a tax rate of 12.0% to 13.0% and excluding any impact from share repurchases. Cash and cash equivalents were $332.9 million at March 31, 2021, and operating cash flow for the quarter was $57.3 million. The press release is furnished rather than filed under Section 18 of the Exchange Act, and the company will hold a conference call on April 27, 2021 at 9:00 a.m. ET to discuss the results.

Apr 26, 2021
8-K
Material AgreementsExhibits & Filings

Medpace Holdings 8-K Report, Material Agreement (Mar 30, 2021)

Medpace Holdings, Inc. disclosed in this Form 8-K, filed March 30, 2021, that on March 29, 2021 its wholly owned subsidiaries Medpace, Inc., as borrower, and Medpace IntermediateCo, Inc., as guarantor, entered into Amendment No. 2 to Loan Documents with PNC Bank, National Association. The amendment relates to an unsecured credit facility with an aggregate principal amount of up to $50 million, governed by a Loan Agreement dated September 30, 2019. The key change is that Amendment No. 2 extends the expiration date of the Loan Agreement to March 31, 2022. The filing states that the description of the amendment is qualified in its entirety by reference to the full document, which is filed as Exhibit 10.1 and incorporated by reference. The filing is limited to this credit facility amendment under Item 1.01 and the related exhibit under Item 9.01. It does not describe any other financial results, operational developments, or changes to borrowing amounts beyond the stated facility size and maturity extension.

Mar 30, 2021
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Feb 16, 2021)

Medpace Holdings, Inc. furnished an 8-K on February 16, 2021 under Item 2.02 (Results of Operations and Financial Condition) attaching a press release dated February 15, 2021 that reports financial results for the three and twelve months ended December 31, 2020. Fourth-quarter 2020 revenue was $259.7 million, up 13.0% from $229.9 million, and full-year 2020 revenue was $925.9 million, up 7.5%. Net new business awards were $358.6 million in the fourth quarter, a net book-to-bill ratio of 1.38x, and $1,175.0 million for the full year, a net book-to-bill ratio of 1.27x. Backlog grew 20.1% to $1.5 billion as of December 31, 2020. Profitability improved over the year. GAAP net income for the fourth quarter was $50.9 million, or $1.35 per diluted share, compared with $29.8 million, or $0.78 per diluted share, a year earlier. Full-year GAAP net income was $145.4 million, or $3.84 per diluted share, versus $100.4 million, or $2.67 per diluted share, in 2019. EBITDA (non-GAAP) was $187.8 million for 2020, up 25.5%, at a 20.3% margin. Cash and cash equivalents totaled $277.8 million at year-end, and the company repurchased about 0.41 million shares in the fourth quarter for $47.4 million, leaving $102.6 million under its repurchase authorization. For 2021, Medpace forecast revenue of $1.075 billion to $1.175 billion, GAAP net income of $154.5 million to $170.5 million, diluted EPS of $4.08 to $4.50, and EBITDA of $205.0 million to $225.0 million. The guidance assumes a 15.0% to 16.0% tax rate and excludes potential share repurchases. The information is furnished rather than filed under Section 18 of the Exchange Act.

Feb 16, 2021
8-K
Other Events

Medpace Holdings 8-K Report, Corporate Update (Oct 30, 2020)

Medpace Holdings, Inc., a Delaware corporation, filed this Current Report on Form 8-K under Item 8.01 (Other Events) to disclose that, as of October 29, 2020, its Board of Directors approved an increase of $50 million to the Company's stock repurchase program. The filing states that the timing, price and volume of repurchases will depend on market conditions, applicable securities laws and other factors. Repurchases may be made from time to time through solicited or unsolicited open market transactions, in privately negotiated transactions, or pursuant to a Rule 10b5-1 plan. The filing also notes that the program may be discontinued or amended at any time without notice. For investors, the key takeaway is the expanded buyback authorization of $50 million, which signals the Board's willingness to return capital to shareholders through share repurchases. The filing does not state how much of the authorization has been used or the size of the program prior to this increase.

Oct 30, 2020
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Oct 26, 2020)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported third quarter 2020 results on October 26, 2020, as furnished in Exhibit 99.1 to this Form 8-K. Revenue rose 6.5% to $230.4 million from $216.2 million a year earlier, and backlog grew 16.7% to $1.4 billion. Net new business awards were $315.4 million, a net book-to-bill ratio of 1.37x. GAAP net income was $41.5 million, or $1.09 per diluted share, compared with $24.0 million, or $0.63 per diluted share, in the prior-year quarter. EBITDA increased 49.4% to $51.9 million, with an EBITDA margin of 22.5%. For full-year 2020, the company forecast revenue of $880.0 million to $920.0 million, GAAP net income of $136.0 million to $144.0 million, and EBITDA of $180.0 million to $190.0 million. Diluted EPS is forecast at $3.62 to $3.83, assuming a 15.0% to 16.0% tax rate. For 2021, the company forecast revenue of $1.050 billion to $1.125 billion and EBITDA of $200.0 million to $220.0 million. At September 30, 2020, cash and cash equivalents were $219.2 million, and operating cash flow for the third quarter was $59.8 million. The company repurchased no shares in the quarter and had $49.2 million remaining under its repurchase program. The board authorized new repurchases bringing the total current authorization to $100 million.

Oct 26, 2020
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Jul 27, 2020)

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished this Form 8-K under Item 2.02 to report its financial results for the three and six months ended June 30, 2020. The full press release is furnished as Exhibit 99.1 and is deemed not 'filed' for purposes of Section 18 of the Exchange Act. For the second quarter of 2020, revenue, net was $205.0 million, down 4.3% from $214.1 million in the prior-year quarter, while net new business awards were $254.1 million, down 9.0% from $279.2 million, producing a net book-to-bill ratio of 1.24x. GAAP net income was $24.1 million, or $0.64 per diluted share, compared with $27.5 million, or $0.73 per diluted share, a year earlier. EBITDA (non-GAAP) was $35.0 million, a 12.9% decrease from $40.2 million, with an EBITDA margin of 17.1% versus 18.8% in the prior-year period. Backlog as of June 30, 2020 grew 14.6% to $1.3 billion from $1.2 billion a year earlier. Cash and cash equivalents were $160.9 million at June 30, 2020, and the company generated $44.3 million in operating cash flow during the second quarter. The company repurchased approximately 0.11 million shares for $7.6 million in the quarter and had $49.2 million remaining under its share repurchase authorization. For full-year 2020, Medpace forecasts revenue of $880.0 million to $920.0 million, growth of 2.2% to 6.9% over 2019 revenue of $861.0 million. Guidance also calls for GAAP net income of $136.0 million to $144.0 million, EBITDA of $180.0 million to $190.0 million, and diluted GAAP EPS of $3.62 to $3.83, assuming a tax rate of 15.0% to 16.0% and no effect from future share repurchases. The company will hold a conference call on July 28, 2020 at 9:00 a.m. ET.

Jul 27, 2020
8-K
Shareholder Matters

Medpace Holdings 8-K Report, Shareholder Vote Results (May 21, 2020)

Medpace Holdings, Inc. held its 2020 Annual Meeting of Stockholders on May 15, 2020, and reported the results in this Item 5.07 Form 8-K filed May 21, 2020. Stockholders re-elected Brian T. Carley, Thomas C. King and Robert O. Kraft as Class I Directors to serve until the 2023 Annual Meeting. Thomas C. King received 31,778,293 votes for and 196,469 withheld, while Brian T. Carley received 20,003,616 votes for and 11,971,146 withheld, and Robert O. Kraft received 19,900,547 votes for and 12,074,215 withheld. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020, with 33,084,140 votes for, 154,417 against and 11,846 abstaining. The most notable outcome was the advisory vote on executive compensation, which was not approved. The proposal received 10,493,264 votes for, 21,455,484 against and 26,014 abstentions, with 1,275,641 broker non-votes. On the frequency of future say-on-pay votes, 31,281,283 votes favored one year, 6,429 favored two years, 671,923 favored three years and 15,127 abstained. Based on these results, and consistent with the Board's recommendation, the Board determined that advisory votes on executive compensation will be submitted to stockholders annually until the next required frequency vote.

May 21, 2020
8-K
Earnings & ResultsExhibits & Filings

Medpace Holdings 8-K Report, Financial Results (Apr 28, 2020)

Medpace Holdings, Inc. (Nasdaq: MEDP) reported first quarter 2020 results for the three months ended March 31, 2020, per a press release furnished as Exhibit 99.1 to this Form 8-K under Item 2.02. Revenue increased 15.0% to $230.9 million from $200.7 million a year earlier, and on a constant currency organic basis revenue rose 15.2%. Backlog grew 16.8% to $1.3 billion as of March 31, 2020. Net new business awards were $246.9 million, a 0.7% decrease from $248.7 million, yielding a net book-to-bill ratio of 1.07x. GAAP net income was $29.0 million, or $0.76 per diluted share, versus $19.2 million, or $0.51 per diluted share, in the prior-year period. EBITDA rose 21.3% to $40.6 million, with an EBITDA margin of 17.6%. The company reported cash and cash equivalents of $134.0 million at March 31, 2020, and operating cash flow of $49.1 million for the quarter. It repurchased approximately 0.7 million shares for $43.2 million during the quarter and had $56.8 million remaining under its share repurchase program. The release emphasizes COVID-19 as a growing headwind. Management said the diversion of resources to treat COVID-19 patients has significantly affected investigative sites, leading to reduced trial starts and slowed new business awards, and that some clients may lack funding to complete trials. Medpace is withdrawing its previously provided revenue, EBITDA, net income, and net income per diluted share guidance and is not issuing new guidance until it can reasonably estimate the pandemic's impact.

Apr 28, 2020
Page 1 of 2